EBS News and Press, Emergent Biosolutions Inc. From 05/20/19

GAITHERSBURG, Md., May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine Vivotif ® (Typhoid Vaccine Live Oral Ty21a) in five additional European Union Member States, i...

GAITHERSBURG, Md., May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the second quarter of 2019: RBC Capital Markets – 2...

GAITHERSBURG, Md., May 15, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has informed the company that it will begin procuring AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) fo...

GAITHERSBURG, Md., May 09, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 23, 2019 beginning at 9:00 AM EDT at the Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard, G...

Emergent BioSolutions Inc. (EBS) Q1 2019 Earnings Conference Call May 2, 2019 5:00 PM ET Company Participants Bob Burrows – Vice President-Investor Relations Bob Kramer – President and Chief Executive Officer Rich Lindahl – Chief Financial Officer Abbey Jen...

Emergent Biosolutions (NYSE: EBS ): Q1 EPS of -$0.13 may not be comparable to consensus of $0.18. More news on: Emergent BioSolutions Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Reaffirms full year 2019 financial forecast and operational goals Provides Q2 2019 revenue forecast of $200M-$220M GAITHERSBURG, Md., May 02, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the three months ended March 31, 2019. FIN...

The FDA grants final approval for Teva Pharmaceutical Industries' (NYSE: TEVA ) generic version of Adapt Pharma's NARCAN Nasal Spray (naloxone HCl), an opioid reversal agent designed to be used by someone with no medical training for treating a person who has overdosed. More news on: T...

GAITHERSBURG, Md., April 18, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, May 2, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2019, recent business developments, revenue guidance for the ...

Preliminary data from a Phase 2 clinical trial evaluating Emergent BioSolutions' (NYSE: EBS ) Fast Track-tagged CHIKV-VLP, its chikungunya virus-like particle vaccine candidate, showed a positive effect. Seroconversion occurred in 74 - 98% of participants by day 7 after a single dose and ...